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http://dxObjective: The study objective was to examine the short- and long-term outcomes of reoperative aortic root
replacement after a previous aortic root replacement.
Methods: From September 1985 to February 2011, 84 consecutive patients underwent reoperative aortic root re-
placement.Thepatients’meanagewas 46 15years (range, 19-80years), and 86%weremen.Themain indication
for reoperation was failed biological or bioprosthetic aortic valve and prosthetic valve endocarditis. Cox propor-
tional hazard regression modeling was performed to identify risk factors that adversely affected overall survival.
Results: The operativemortality was 6% (5 patients). Perioperativemorbidity includedmyocardial infarction in
2 patients, low cardiac output syndrome in 7 patients, sepsis in 3 patients, pulmonary complications in 7 patients,
renal failure in 3 patients, reoperation for bleeding or tamponade in 5 patients, superficial sternal wound infec-
tions in 3 patients, permanent transvenous pacemaker in 8 patients, and stroke in 1 patient. Kaplan–Meier esti-
mates for survival at 5, 10, and 12 years were 82.5% 4.7%, 72.5% 6.4%, and 65.0% 7.6%, respectively;
the freedom from reoperation was 100%, 92.3%  5.2%, 92.3%  5.2%, respectively; and valve-related
mortality was 93.1%  3.4%, 90.8%  4.0%, and 86.2%  5.8%, respectively. During the follow-up,
valve-related deaths occurred in 7 patients. Age by increments of 5 years (hazard ratio, 1.205; 95% confidence
interval, 1.036-1.401) and prosthetic valve endocarditis (hazard ratio, 2.662; 95% confidence interval,
1.054-6.724) were independent risk factors for mortality.
Conclusions:Aortic root replacement after a previous aortic root replacement is associated with a relatively low
operative mortality and perioperative morbidity, but long-term survival is suboptimal. Increasing age and pros-
thetic valve endocarditis adversely affect survival. (J Thorac Cardiovasc Surg 2013;146:611-5)A
C
DIn 1968, Bentall and De Bono1 described an operation using
a tubular graft and a prosthetic valve for combined replace-
ment of the ascending aorta and aortic valve with reimplan-
tation of the coronary arteries. Forty years later and after
several technical modifications, this operation has become
an essential part of the surgical armamentarium to treat pa-
tients with aortic root disease.2-5 Sioris and colleagues,6
from Toronto General Hospital, reported an operative mor-
tality for the modified Bentall procedure of 4% in patients
who underwent operation between 1990 and 2001, and
many other series have reported similar operative mortal-
ity.6-10 However, despite extensive evidence of safety of
the modified Bentall procedure as a first cardiac surgical
intervention, there is limited information regarding the
clinical outcomes of this operation after a previous aortic
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The Journal of Thoracic and Careplacement (ARR). In 2007, Szeto and colleagues11 re-
ported a 30-day mortality of 11.5% in 156 patients who un-
derwent a reoperative ARR after a previous aortic valve
replacement. Raanani and colleagues,12 from Toronto
General Hospital, reported an operative mortality of 3%
in a small consecutive series of 31 patients who had under-
gone a previous Bentall procedure.
The objective of this study was to examine the short- and
long-term outcomes of ARR as a reoperative surgery after
a previous ARR.PATIENTS AND METHODS
From September 1985 to February 2011, 84 patients underwent ARR as
a reoperative procedure after ARR. The interval between the first ARR and
the redo ARR was 11.5  7.3 years. The patients’ clinical profile, the type
of valve used in the previous ARR, and the indications for reoperations are
summarized in Table 1. Most patients had undergone only 1 previous ARR,
but 3 patients had undergone 2 previous ARRs, and 2 patients had under-
gone 3 previous ARRs in this series.
Operations were performed following standard techniques for ARR
whenever possible. Certain modifications were needed for more complex
aortic root pathology, particularly cases of aortic root abscess with exten-
sive destruction of the aortoventricular junction and surrounding struc-
tures.12-16 Table 2 summarizes the operative data.
Twenty-two patients underwent ARR by suturing a tubular Dacron graft
to the left ventricular outflow tract (LVOT), reimplanting the coronary ar-
teries to this conduit, and implanting a bioprosthetic or mechanical aortic
valve inside the Dacron graft.14 The rationale for this technique was tordiovascular Surgery c Volume 146, Number 3 611
Abbreviations and Acronyms
ARR ¼ aortic root replacement
LVOT ¼ left ventricular outflow tract
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Dbe able to tailor the Dacron graft to any defect in the LVOTand to allow for
reimplantation of the coronary arteries without having to interpose a graft
between the main conduit and the coronary arteries. However, an interpo-
sition graft of Dacron or saphenous vein between a main coronary artery
and the neoaortic root was used in 19 patients (in the right coronary artery
in 3, in the left main artery in 6, and in both main arteries in 10). Most of
these grafts were less than 2 cm in length.
The research ethics board of Toronto General Hospital approved this
study, and patient consent was waived considering the observational study
design.
The primary end point of this study was survival after surgery. Operative
mortality was defined as any death in hospital or during the first 30 postop-
erative days. Perioperative complications were analyzed, such as myocar-
dial infarction, low cardiac output syndrome, stroke, renal failure, wound
infection, sepsis, pulmonary complications, atrial fibrillation, use of
intra-aortic balloon pump, need for inotropes, duration of assisted ventila-
tion, and length of stay in intensive care unit and hospital. Secondary end
points were freedom from reoperation on the aortic valve for any cause and
freedom from valve-related death.
The following preoperative variables were examined for the potential
effect on outcomes: age, sex, body surface area, New York Heart Associa-
tion functional class, congestive heart failure, angina, urgent or emergency
surgery, previous coronary artery bypass, preoperative shock, severe
chronic obstructive pulmonary disease (forced expiratory volume< 1.0
L/s), left ventricular ejection fraction, diabetes mellitus, hypertension, hy-
perlipidemia, peripheral vascular disease, active endocarditis, remote or ac-
tive endocarditis, previous stroke or transient ischemic attack, atrial
fibrillation, preoperative renal failure, Marfan syndrome, cardiopulmonary
bypass and aortic clamping times, and technical aspects of the surgery, such
as type of valve explanted, technique of coronary artery reimplantation, and
combined operative procedures.
All data were prospectively collected and validated by a full-time re-
search team. Follow-up data were obtained from electronic patient records
and updated by telephone interviews. The median follow-up was 5.5 years,
and the mean follow-up was 5.0 years (0-20.9 years). The follow-up was
100% complete.
Statistical Analysis
Categoric variables are reported as number and percentages. Continu-
ous variables are expressed as mean  standard deviation or median and
interquartile range when appropriate. All statistical analyses were per-
formed with SAS 9.1 software (SAS Institute, Inc, Cary, NC). Statistical
analysis was performed using the chi-square test or Fisher exact test for
categoric variables and t tests or Wilcoxon rank-sum test for continuous
variables depending on the distribution. No multiple imputation or adjust-
ments for multiplicity were considered. Cox proportional hazard regression
modelingwas performed to identify predictors of survival.17 Kaplan–Meier
curves were constructed using STATA SE 11.2 (StataCorp LP, College Sta-
tion, Tex). Kaplan–Meier curves were plotted up to 150 months of follow-
up to maintain a meaningful minimum of 10% of the population at risk.
RESULTS
Perioperative Mortality and Morbidity
The operative mortality was 6% (5 patients). The causes
of death were ruptured thoracoabdominal aortic aneurysm
in 1 patient, technical problems related with bleeding612 The Journal of Thoracic and Cardiovascular Surgduring surgery for an extensive aortic root abscess in 1 pa-
tient, multiorgan failure in 1 patient, unexplained cardiac
arrest in 1 patient, and sudden death in 1 patient. Perioper-
ative morbidity is presented in Table 3.
Patients’ Survival
There were 5 operative and 15 late deaths. The causes of
late death were endocarditis in 4 patients, congestive heart
failure in 2 patients, cancer in 2 patients, hemophilia in 1 pa-
tient, coagulopathy in 1 patient, anticoagulation-related
hemorrhage in 1 patient, motor vehicle accident in 1 patient,
myocardial infarction in 1 patient, sudden death in 1 patient,
and death after back surgery in 1 patient. Patients’ survivals
at 5, 10, and 12 years were 82.5% 4.7%, 72.5% 6.4%,
and 65.0%  7.6%, respectively (Figure 1).
Freedom From Reoperation on the Aortic Valve for
Any Reason
During the follow-up, 4 patients underwent reoperation.
The causes for reoperation were prosthetic valve endocardi-
tis in 2 patients, tissue valve failure in 1 patient, and sub-
aortic stenosis with mitral stenosis in 1 patient. All 4
patients survived reoperation. Freedom from reoperation
on the aortic valve for any reason at 5, 10, and 12 years
was 100%, 92.3%  5.2%, and 92.3%  5.2%, respec-
tively (Figure 2). Reoperations were performed at 99,
102, 155, and 251 months.
Freedom From Structural Valve Deterioration
Structural valve deterioration developed in 1 patient at
155 months of follow-up. Freedom from reoperation on
the aortic biological/bioprosthetic valve (n ¼ 30) for any
reason up to 12 years was 100%.
Freedom From Valve-Related Mortality
Seven patients died of valve-related causes: prosthetic
valve endocarditis in 4 patients, sudden death in 1 patient,
coagulopathy in 1 patient, and anticoagulant-related hemor-
rhage in 1 patient. The valve-related mortality event was at
4, 21, 33, 54, 71, 122, and 152 months of follow-up. Freedom
from valve relatedmortality at 5, 10, and 12 years was 93.1%
 3.4%, 90.8%  4.0%, and 86.2%  5.8%, respectively.
Cox Proportional Hazard Regression Analyses for
Death From Any Cause
The only 2 variables predictive of death from any cause
were age by increments of 5 years (hazard ratio, 1.20;
95% confidence interval, 1.03-1.40) and prosthetic valve
endocarditis (hazard ratio, 2.66; 95% confidence interval,
1.05-6.72).
DISCUSSION
Given the technical challenges of performing an ARR in
a patient who already underwent one, we decided toery c September 2013
TABLE 1. Clinical profile and indications for reoperation
No. of patients 84 (100)
Mean age  SD (range) 46  15 (19-80) y
Body surface area  SD, 1.96  0.26 m2
Male gender 72 (86)
Urgent/emergency surgery 11 (13)
NYHA class IV 36 (43)
Congestive heart failure 48 (57)
Angina pectoris 11 (13)
Preoperative shock 2
Electrocardiogram
Sinus rhythm 76 (90)
Atrial fibrillation 4







Previous stroke 10 (12)
Marfan syndrome 8
Chronic type A aortic dissection 5
Prosthetic valve infective endocarditis




Aortic root homograft 32 (38)
Medtronic Freestyle (Medtronic Inc,
Minneapolis, Minn) root
14 (17)
Bioprosthesis in Dacron tube 17 (20)
Ross procedure 7 (8)
Mechanical valve 14(17)
CABG 2
Pulmonary valve replacement 7
Resection of subaortic membrane 2
Repair of ventricular septal defect 2
Mitral valve repair/replacement 5
Tricuspid valve repair 1
Indication for surgery
Prosthetic valve/graft endocarditis 18
Failed biological or bioprosthetic valve 55
Stenotic mechanical valve (pannus) 9
Subaortic stenosis and false aneurysm 1
Subaortic false aneurysm 1
Percentages are shown in parentheses. SD, Standard deviation; NYHA, New York
Heart Association; COPD, chronic obstructive pulmonary disease (forced expiratory
volume<1 L/s); ARR, aortic root replacement; CABG, coronary artery bypass graft
surgery.
TABLE 2. Operative data
Operations performed No.
Aortic root re-replacement 84
Reconstruction of LVOT 4
Mitral valve replacement 9
Reconstruction of the mitral annulus 2
Mitral valve repair 8
Tricuspid valve repair 1
Coronary artery bypass graft 12
Left main/right coronary artery graft
interposition
19
Hemi- or total arch replacement 11
Pulmonary valve re-replacement 3
Aortic valves implanted at reoperation:
Mechanical valves 54
Bioprosthetic valve into a Dacron tube 10
Medtronic Freestyle 9
Aortic root homograft 9
Ross procedure 2
Aortic valve (mechanical and bioprosthetic) sizes:
Range of sizes 21-29
Mean size  SD 26  2
Cardiopulmonary bypass time  SD 149  55 min
Aortic clamping time  SD 117  41 min
LVOT, Left ventricular outflow tract; SD, standard deviation.
TABLE 3. Perioperative adverse events
Variable No.
Operative mortality 5
ICU stay (mean  SD) 33  33 h
Assisted ventilation (mean  SD) 8  10 h
Reexploration for bleeding 5
Stroke 1
Perioperative myocardial infarction 2
Sepsis 3
Pulmonary complications 7
Superficial sternal wound infection 3
Renal failure 3
Low cardiac output syndrome 7
Intra-aortic balloon pump 5
Permanent transvenous pacemaker 8
Transient new atrial fibrillation 12
Hospital stay (mean  SD) 7  3 d
ICU, Intensive care unit; SD, standard deviation.
Garrido-Olivares et al Acquired Cardiovascular Disease
A
C
Dexamine the outcomes of this type of reoperation. To the
best of our knowledge, observational studies addressing
the clinical course and long-term outcomes of patients un-
dergoing ARR after a previous ARR have not been reported.
In 2001, we reported our experience with 31 patients who
underwent redo ARR and indicated that interposition of
a graft to extend 1 or both coronary arteries was necessaryThe Journal of Thoracic and Cain approximately one half of the patients, and we expressed
concerns about this technique.12 Although we have tried to
avoid this technique, our experience suggests that it has no
apparent adverse effect on survival or any other clinical
outcome.
Reoperative ARR is complex, and every step of the pro-
cedure is important. We pay extreme attention to myocar-
dial protection and patency of the coronary arteries. We
always start a redo ARR by detaching the coronary arteries
from the old graft and making sure that they are patent and
that there is enough tissue around the orifice to reimplantrdiovascular Surgery c Volume 146, Number 3 613
FIGURE 1. Kaplan–Meier estimates of patients’ survival.
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Dthem safely. If there is inadequate aortic wall around the or-
ifice of the coronary artery, we suture a 6-mm Dacron graft
or a large saphenous vein in an end-to-end fashion to give
cardioplegia during the procedure and to facilitate reim-
plantation of the artery later. Next, the valved conduit is re-
moved from the aortoventricular junction. Depending on
the pathology, parts of the LVOT have to be excised along
with the valved conduit. When this happens, we prefer to
use a custom-made conduit instead of commercially
available conduits. A tubular Dacron graft is tailored to fit
the defective LVOTand sutured to it with a continuous poly-
propylene suture.14 The coronary arteries are reimplanted
next, and a valve is implanted into the conduit. Patients
with aortic root abscess require more extensive resection
and reconstruction of the LVOT before a valved conduit
can be implanted. Although we do favor an aortic valve ho-
mograft in these patients, we continue to believe that radical
resection of all infected tissues and reconstruction with
patches is probably more important than the type of valve
implanted.18 In addition, the intervalvular fibrous bodyFIGURE 2. Kaplan–Meier estimates for freedom from reoperation.
614 The Journal of Thoracic and Cardiovascular Surgand anterior leaflet of the mitral valve may be involved
and destroyed by the abscess, and mitral valve replacement
may be necessary.18
Our cohort of 84 patients had at least 1 previous ARR and
required a reoperation. The principal reason for reoperation
on patients who had a previous ARR was biological or bio-
prosthetic valve failure. The operative mortality was 6%,
and perioperative morbidity was probably similar to that
for most heart valve reoperations, but we had a relatively
high incidence of complete heart block requiring permanent
pacemaker. In addition, a 10-year survival just less than
73% is worrisome because our patients’ mean age was
only 46 years when they had the redo ARR. Although pros-
thetic valve endocarditis understandably may have a nega-
tive effect on survival, it is unclear to us why age by
increments of 5 years played a role in late survival given
the relative young age of our patients.
Kouchoukos and colleagues4 reported an operative mor-
tality of 5.2% in a series of 172 patients who underwent the
modified Bentall procedure between 1974 and 1990. This
was one of the first series of Bentall procedures published,
but the current operative mortality is probably less than
5.2% in first-time operations.3,7,8,10 Despite the fact that
our series included patients who underwent operation as
far back as 1985, the operative mortality of 6% is likely
more a reflection of the technical challenges of this
reoperative procedure than a temporal bias.
Recent series of the modified Bentall procedure de-
scribed operative mortality ranging from 2.9% to
5.2%.3,7,19 In a study of 597 patients undergoing the
modified Bentall procedure from 1995 to 2008, Etz and
colleagues7 reported a 30-day mortality of 3.9%. Their
study also provided strong evidence that the type of valve
used in this setting had no impact on short- and long-term
outcomes. In relation to these recent studies, our results
compare favorably in terms of operative mortality.
In 2010, Bekkers and colleagues20 reported 41 patients
who underwent ARR after a Ross procedure using the
ARR technique between 1988 and 2009. There was no mor-
tality at 30 days, and the 5-year survival was 94%. The
mean age was 36 years, and 33 patients required isolated
pulmonary autograft replacement and 8 patients required
replacement of the pulmonary autograft and homograft.
Although that study deals with only 1 type of redo ARR,
it reinforces the view that redo ARR is a safe operation.
Finally, the operative mortality for redo aortic valve re-
placement ranges from 2.3% to 17.6%.21 In a recent study
by Leontyev and colleagues21 on 155 patients with redo aor-
tic valve replacement, the 30-day mortality was 4.5% and
the in-hospital mortality was 5.8%. There is no doubt that
reoperations on heart valves are associated with increased
operative mortality and morbidity, but the risk for redo
ARR seems similar to that for redo aortic valve
replacement.ery c September 2013
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DStudy Limitations
This is a retrospective study and is associated with all the
limitations of this type of study. An experienced heart valve
surgeon performed operations on most patients, and the
results may not be generalizable. In addition, the sample
size was relatively small and the pathology was heteroge-
neous for a meaningful statistical analysis.
CONCLUSIONS
The results of this study on ARR after a previous ARR
showed that the operative mortality and morbidity are
relatively low and probably similar to those for other reo-
perative heart valve surgeries. The long-term survival is
suboptimal, and advancing age and prosthetic valve endo-
carditis were found to be independent predictors of
mortality.
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